Biopharma Ltd. (QNTM) adds material change reports to existing Form F-3

Rhea-AI Filing Summary

Biopharma Ltd. furnished a Form 6-K as a foreign private issuer, primarily to update disclosure linked to its existing Form F-3 registration statement. The filing states that Exhibits 99.3 through 99.11, each a material change report dated between July 3, 2024 and September 30, 2025, are incorporated by reference into that Form F-3 and deemed part of it from the date this report is furnished, unless later superseded. The report is signed on behalf of the company by Chief Financial Officer Donal Carroll.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39152

QUANTUM BIOPHARMA LTD.

(Registrant)

1 Adelaide Street East, Suite 801

Toronto, Ontario M5C 2V9

(Address of Principal Executive Offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

DOCUMENTS INCORPORATED BY REFERENCE

Exhibits 99.3 through 99.11 of this Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	QUANTUM BIOPHARMA LTD.
	(Registrant)
Date October 28, 2025	By	/s/ Donal Carroll
		Donal Carroll
		Chief Financial Officer

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Material Change Report dated February 6, 2024
99.2		Material Change Report dated February 26, 2024
99.3		Material Change Report dated July 3, 2024
99.4		Material Change Report dated August 23, 2024
99.5		Material Change Report dated August 29, 2024
99.6		Material Change Report dated September 13, 2024
99.7		Material Change Report dated September 19, 2024
99.8		Material Change Report dated October 3, 2024
99.9		Material Change Report dated March 17, 2025
99.10		Material Change Report dated June 27, 2025
99.11		Material Change Report dated September 30, 2025

FAQ

What did Biopharma Ltd. (QNTM) file in this Form 6-K?

Biopharma Ltd. filed a Form 6-K to update its disclosure by furnishing multiple material change reports. The company also specifies that certain exhibits are incorporated by reference into its existing Form F-3 registration statement and become part of that document from the filing date.

Which exhibits from Biopharma Ltd.’s Form 6-K are incorporated into its Form F-3?

Exhibits 99.3 through 99.11 are incorporated by reference into Biopharma Ltd.’s Form F-3. These exhibits consist of material change reports dated between July 3, 2024 and September 30, 2025 and are deemed part of the registration statement from this Form 6-K’s furnishing date.

What types of documents are listed as exhibits in Biopharma Ltd.’s Form 6-K?

The exhibit index lists a series of material change reports as Exhibits 99.1 through 99.11. Each exhibit corresponds to a specific material change report dated between February 6, 2024 and September 30, 2025, reflecting various corporate developments over that period.

Who signed Biopharma Ltd.’s October 2025 Form 6-K and in what capacity?

The Form 6-K was signed on behalf of Biopharma Ltd. by Donal Carroll. He signs in his role as Chief Financial Officer, indicating he is duly authorized to sign the report under the Securities Exchange Act of 1934 on the company’s behalf.

How does this Form 6-K affect Biopharma Ltd.’s existing Form F-3 registration?

The Form 6-K causes certain material change reports to become part of Biopharma Ltd.’s Form F-3. By incorporating Exhibits 99.3 through 99.11 by reference, the registration statement’s disclosure is updated to reflect information contained in those reports.